Plasminogen Therapy for Obesity With Safer Fat Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current weight-loss drugs for obesity have limited efficacy and safety concerns, necessitating the development of safer and more effective treatments.
Innovation Solution
Utilizing plasminogen as a weight-loss drug to address obesity by improving abnormal fat deposition and reducing body weight, administered alone or in combination with other therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing weight-loss drugs are used, then weight reduction can be achieved, but safety concerns and limited efficacy arise
Solution Approach 1:
The patent changes the biochemical parameter by introducing plasminogen, a different molecular mechanism compared to existing drugs. Plasminogen activates plasmin which degrades extracellular matrix and adipose tissue, representing a fundamental parameter change in the weight loss mechanism that achieves both safety and efficacy
2Ease of operation
If central appetite suppressants are used, then appetite control is improved, but mental and cardiovascular disease risks increase
Solution Approach 1:
The patent uses plasminogen as an intermediary substance that indirectly affects appetite and weight through plasmin activation and extracellular matrix degradation, rather than directly suppressing appetite centers in the brain. This intermediary mechanism avoids the harmful central nervous system effects of traditional appetite suppressants
3Reliability
If lifestyle intervention is used, then safety is maintained, but weight loss effectiveness is insufficient when BMI ≥ 28
Solution Approach 1:
The patent segments the weight loss mechanism into distinct biochemical pathways: plasminogen activation, plasmin generation, extracellular matrix degradation, and adipose tissue breakdown. This segmented approach targets specific metabolic pathways to achieve effective weight loss in severe obesity cases while maintaining safety
Data Source
Figure 1~3
Figure 4A~6
Figure 7~9
AI summary
The present invention relates to a method for preventing and/or treating overweight/obesity and their related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from obesity and its related conditions, to reduce an abnormal/excessive fat deposition at various sites of the body. The present invention further relates to a medicament for preventing and/or treating obesity, and its use in the preparation of a medicament.